HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Esmolol
ESMOLOL USP/EP/BP · Methyl 3-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]propionate · Methyl 3-(4-(2-hydroxy-3-(isopropylaMino)propoxy)phenyl)propanoate hydrochloride · Methyl 3-{4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl}propanoate hydrochloride (Esmolol HCl)
Identifikatoren & physikalische Daten
| CAS No. | 103598-03-4 |
|---|---|
| Summenformel | C16H25NO4 |
| Durchschnittliche Molmasse | 295,37 g/mol |
| Monoisotopische Masse | 295,17835828 g/mol |
| SMILES | COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1 |
| InChIKey | AQNDDEOPVVGCPG-UHFFFAOYSA-N |
| PubChem CID | 59768 |
| ChEMBL | CHEMBL768 |
| ChEBI | CHEBI:88206 |
| DTXSID | DTXSID4022995 |
Chemische & physikalische Eigenschaften
| XLogP | 1,9 |
|---|---|
| Polarare Oberfläche (TPSA) | 67,8 |
| H-Brücken-Donoren | 2 |
| H-Brücken-Akzeptoren | 5 |
| Frei drehbare Bindungen | 10 |
| Schwere Atome | 21 |
| Formalladung | 0 |
| Komplexität | 288 |
| Arzneimittel | PharmaceuticalsPharmaceuticals -> Antihypertensives |
| LogP (Verteilungskoeffizient) | 1.7 |
| Löslichkeit | Very soluble as hydrochloride salt1.44e-01 g/L |
| Human Drugs | Breast FeedingLactationMilk, HumanAntihypertensive AgentsAdrenergic Beta-AntagonistsAntiarrhythmicsPharmaceuticals |
| Physical Description | Solid |
| Schmelzpunkt | 48-50°C |
| Dichte | 1.026 |
Sicherheit & Vorschriften
| Hepatotoxicity | Esmolol therapy has not been clearly associated with serum aminotransferase elevations or with clinically apparent, acute liver injury. It is often used in critically patients and generally for a short period only. Thus, hepatotoxicity due to esmolol must be very rare, if it occurs at all. Most commonly used beta-blockers have been linked to rare instances of clinically apparent liver injury, typically with onset within 2 to 12 weeks, a hepatocellular pattern of liver enzyme elevations, rapid recovery upon withdrawal, and little evidence of hypersensitivity (rash, fever, eosinophilia) or autoantibody formation. Similar instances have not been reported after esmolol use. |
|---|---|
| Unerwünschte Wirkungen | * The most common adverse reaction with esmolol is hemodynamic compromise, which happens to over 10% of all patients. |
| Toxizitätsübersicht | Signs and Symptoms of Overdose |
| Drug Induced Liver Injury | Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)esmololBrevibloc®Beta blockersNot Applicableno-DILI-concern |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| Alarmwort | Warnung |
| Gefahrenhinweise | Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H315 |
Anwendungen & Verwendung
Verwenden
Anti-adrenergic (β-receptor).